Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EXACT Therapeutics AS ( (DE:56F) ) has shared an update.
EXACT Therapeutics announced that data from its ACTIVATE Phase 1 trial, focusing on liver metastases of colorectal origin, will be presented at the ESMO Congress 2025. This presentation highlights the potential impact of their Acoustic Cluster Therapy in enhancing chemotherapy effectiveness, potentially influencing future treatment protocols and strengthening EXACT’s position in precision oncology.
More about EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage precision medicine company that leverages ultrasound and microbubbles for targeted drug delivery in oncology. Their Acoustic Cluster Therapy (ACT®) is designed for use with various therapeutic agents, applicable in oncology and other conditions like brain diseases. The company’s shares are listed on Euronext Growth Oslo.
Average Trading Volume: 33,732
Current Market Cap: NOK174.6M
For a thorough assessment of 56F stock, go to TipRanks’ Stock Analysis page.